1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Jonathan W. Riess(University of California Davis Medical Center), Ainara Soria Rivas(Hospital Universitario Ramón y Cajal), Marya Chaney(Merck & Co., Inc., Rahway, NJ, USA (United States)), James Spicer(King's College London), Marta Iglesias(Hospital Del Mar), J. Rubio Perez(Hospital Universitario Fundación Jiménez Díaz), P.H. Shaw(Velindre NHS Trust), Priyanka Patel(GenProMarkers (United States)), V. Villaflor(City of Hope), Q. Ahmad(Ayub Medical College), C F Abildgaard(University of California, Davis), Dermot T. McDowell(Galecto (Denmark)), T. Seiwert(University of Chicago)
Cited by 3
Related Papers
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
|Journal of Clinical Oncology|2021|1.1k
Non–Small Cell Lung Cancer, Version 4.2024
|Journal of the National Comprehensive Cancer Network|2024|805
siRNA-directed inhibition of HIV-1 infection
|Nature Medicine|2002|777
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|670